A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022*

Download All
2022 ASCO Annual Meeting, June 3-7, 2022, in Chicago, Illinois, USA; EHA 2022 Congress, June 9-12, 2022, in Vienna, Austria; 2022 Pan Pacific Lymphoma Conference, July 18-22, 2022, in Koloa, Hawaii, USA; ESMO 2022 Annual Congress, September 9-13, 2022, in Paris, France; 2022 SOHO Annual Meeting, September 28 - October 1, 2022, in Houston, Texas, USA
Get up to date on emerging data with BTK inhibitors for chronic lymphocytic leukemia and mantle cell lymphoma presented at the 2022 meetings of ASCO, EHA, Pan Pacific Lymphoma, ESMO, and SOHO with on-demand webcasts, expert podcasts, downloadable slides, commentaries, and a “year in review” module.
Othman Al-Sawaf, MD
Matthew S. Davids, MD, MMSc
Toby Eyre, MBChB, MD
Christopher R. Flowers, MD, MS
Brad S. Kahl, MD
Kami Maddocks, MD
Anthony Mato, MD, MSCE
Lydia Scarfò, MD
Jeff Sharman, MD
Julie M. Vose, MD, MBA

Downloadable Slideset

Download this living slideset featuring new data from conference presentations on the use of BTK inhibitors to treat CLL and MCL. This slideset will be updated throughout 2022 and include key findings from the ASCO, EHA, Pan Pacific, ESMO, and SOHO annual meetings, so check back often.

Othman Al-Sawaf, MD Anthony Mato, MD, MSCE Lydia Scarfò, MD Julie M. Vose, MD, MBA Released: October 10, 2022

ClinicalThought

In this commentary, 2 experts discuss important recent clinical trials reported at ASCO 2022 that may impact treatment for chronic lymphocytic leukemia and mantle cell lymphoma.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: June 30, 2022

Dans ce commentaire, deux experts discutent d'importants essais cliniques récents qui furent rapportés lors de l'ASCO 2022, et qui pourraient avoir un impact sur le traitement de la leucémie lymphoïde chronique et du lymphome à cellules du manteau.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 12, 2022

In dieser Stellungnahme erörtern 2 Experten wichtige neue klinische Studien, die auf der Jahrestagung der ASCO 2022 vorgestellt wurden und die möglicherweise die Behandlung der chronischen lymphatischen Leukämie und des Mantelzell-Lymphoms beeinflussen werden.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 12, 2022

In questo approfondimento, 2 esperti discutono sui recenti e importanti risultati degli studi clinici presentati all'ASCO 2022, che potrebbero avere un impatto sul trattamento della leucemia linfocitica cronica e del linfoma a cellule mantellari.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 12, 2022

Neste comentário, dois especialistas discutem importantes ensaios clínicos recentes relatados na ASCO 2022 que podem impactar no tratamento da leucemia linfocítica crônica e do linfoma de células do manto.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 12, 2022

En este comentario, dos expertos hablan sobre los importantes ensayos clínicos recientes abordados en ASCO 2022 que podrían afectar al tratamiento de la leucemia linfocítica crónica y el linfoma de células del manto.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 12, 2022

In this commentary, 2 experts discuss the implications of clinical trial data presented at EHA 2022 on BTK inhibitor–based treatments for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: July 20, 2022

Dans ce commentaire, deux experts discutent des implications des données d’essais cliniques présentées à l’EHA 2022 sur les traitements basés sur des inhibiteurs de BTK pour les patients atteints de leucémie lymphocytaire chronique (LLC) et de lymphome à cellules du manteau (LCM).

Released: August 15, 2022

In dieser Stellungnahme diskutieren 2 Experten die Auswirkungen der auf der EHA 2022 vorgestellten Daten aus klinischen Studien zu BTK-Inhibitoren–basierten Behandlungen für Patienten mit chronischer lymphatischer Leukämie und Mantelzell-Lymphom.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

In questa intervista, due esperti discutono i dati degli studi clinici sugli inibitori di BTK nel trattamento della leucemia linfatica cronica (CLL) e del linfoma mantellare (MCL) presentati al Congresso EHA 2022.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

Neste comentário, dois especialistas discutem as implicações dos dados de ensaios clínicos apresentados no EHA 2022 sobre tratamentos baseados em inibidores de BTK para pacientes com leucemia linfocítica crônica e linfoma de células do manto.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

En este comentario, 2 expertos hablan sobre las implicaciones de los datos de ensayos clínicos presentados en la EHA 2022 sobre los tratamientos basados en inhibidores de la TQB para pacientes con leucemia linfocítica crónica y linfoma de células del manto.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

In this commentary, 2 experts discuss the implications of clinical trial data presented at the 2022 Pan Pacific Lymphoma Conference on BTK inhibitor–based treatments for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 23, 2022

Dans ce commentaire, deux experts discutent des implications des données d'essais cliniques présentées lors de la Pan Pacific Lymphoma Conference de 2022 sur les traitements à base d'inhibiteurs de BTK pour les patients atteints de leucémie lymphocytaire chronique (LLC) ou de lymphome à cellules du manteau (LCM).

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 30, 2022

In dieser Stellungnahme diskutieren zwei Experten die Auswirkungen der auf der Pan Pacific Lymphoma Conference 2022 vorgestellten Daten aus klinischen Studien zu auf BTK-Inhibitoren basierten Behandlungen für Patienten mit chronischer lymphatischer Leukämie und Mantelzell-Lymphom.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 31, 2022

In questa intervista, due esperti discutono i dati degli studi clinici sugli inibitori di BTK nel trattamento della leucemia linfatica cronica (CLL) e del linfoma mantellare (MCL) presentati alla Conferenza Pan Pacific Lymphoma 2022.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 31, 2022

Neste comentário, dois especialistas discutem as implicações dos dados de ensaios clínicos apresentados na Conferência Pan-Pacífico sobre Linfomas 2022, sobre tratamentos baseados em inibidores de BTK para pacientes com leucemia linfocítica crônica e linfoma de células do manto.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 31, 2022

En este comentario, 2 expertos hablan sobre las implicaciones de los datos de ensayos clínicos presentados en la Conferencia del Pacífico sobre el Linfoma de 2022 a partir de los tratamientos basados en inhibidores de la TQB para pacientes con leucemia linfocítica crónica y linfoma de células del manto.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 31, 2022

In this commentary, expert faculty address frequently asked questions on current and emerging management strategies with BTK inhibitors for patients with CLL and MCL.

Othman Al-Sawaf, MD Toby Eyre, MBChB, MD Released: October 19, 2022

In this commentary, expert faculty address frequently asked questions on current and emerging management strategies with BTK inhibitors for patients with CLL and MCL.

Othman Al-Sawaf, MD Toby Eyre, MBChB, MD Released: November 1, 2022

In this commentary, expert faculty address frequently asked questions on current and emerging management strategies with BTK inhibitors for patients with CLL and MCL.

Othman Al-Sawaf, MD Toby Eyre, MBChB, MD Released: November 2, 2022

In this commentary, expert faculty address frequently asked questions on current and emerging management strategies with BTK inhibitors for patients with CLL and MCL.

Othman Al-Sawaf, MD Toby Eyre, MBChB, MD Released: November 2, 2022

In this commentary, 2 experts discuss the implications of clinical trial data presented at the SOHO 2022 Annual Meeting on BTK inhibitor–based treatments for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 16, 2022

LLC et LCM : réunion annuelle de la SOHO 2022 Dans ce commentaire, deux experts discutent des implications des données d’essais cliniques présentées lors de la réunion annuelle de la SOHO 2022 sur les traitements à base d’inhibiteurs BTK pour les patients atteints de leucémie lymphoïde chronique (LLC) ou de lymphome à cellules du manteau (LCM).

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

In dieser Stellungnahme diskutieren 2 Experten die Auswirkungen der auf der Jahresversammlung der SOHO 2022 vorgestellten Daten aus klinischen Studien zu BTK-Inhibitor-basierten Behandlungen für Patienten mit chronischer lymphatischer Leukämie und Mantelzell-Lymphom.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

In questa discussione, due esperti discutono delle implicazioni derivanti dai dati degli studi clinici presentati alla Conferenza annuale della SOHO 2022 relativi ai trattamenti con inibitori di BTK nei pazienti con leucemia linfatica cronica e linfoma mantellare.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Neste comentário, dois especialistas discutem as implicações dos dados de ensaios clínicos apresentados na Reunião Anual da SOHO 2022 sobre tratamentos baseados em inibidores de BTK para pacientes com leucemia linfocítica crônica e linfoma de células do manto.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

En este comentario, 2 expertos hablan sobre las implicaciones de los datos de ensayos clínicos presentados en la Junta Anual de SOHO 2022 sobre los tratamientos basados en inhibidoresde la TQB para pacientes con leucemia linfocítica crónica y linfoma de células del manto.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Podcasts

Gain insight into expert faculty perspectives as they discuss recent key studies from ASCO 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 6, 2022

Gain insight into expert faculty perspectives as they discuss recent key studies from EHA 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: July 21, 2022

Gain insight from expert perspectives on key studies from the Pan Pacific Lymphoma Conference 2022 covering BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and the potential implications for clinical practice.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 30, 2022

Listen to expert perspectives on select studies from the SOHO 2022 Annual Meeting covering BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and the potential implications for clinical practice.

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: October 28, 2022

On-Demand Webcasts

In this on-demand webcast from a live symposium, experts Othman Al-Sawaf, MD, and Toby Eyre, MBChB, MD, discuss current and emerging data on BTK inhibitor therapy for the treatment of patients with CLL and MCL.

Othman Al-Sawaf, MD Toby Eyre, MBChB, MD Released: October 21, 2022

Watch this on-demand webcast capturing a dynamic workshop in which 3 experts discuss best practices and future directions in the use of BTK inhibitors for chronic lymphocytic leukemia and mantle cell lymphoma.

Matthew S. Davids, MD, MMSc Anthony Mato, MD, MSCE Jeff Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 22, 2022 Expired: November 21, 2023

Year in Review

Review expert perspectives and insights on the most clinically relevant data for chronic lymphocytic leukemia and mantle cell lymphoma presented at the 2022 Annual Meetings of ASCO, EHA, Pan Pacific Lymphoma Conference, ESMO, and SOHO.

Othman Al-Sawaf, MD Matthew S. Davids, MD, MMSc Toby Eyre, MBChB, MD Christopher R. Flowers, MD, MS Brad S. Kahl, MD Kami Maddocks, MD Anthony Mato, MD, MSCE Lydia Scarfò, MD Julie M. Vose, MD, MBA Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 16, 2022 Expired: December 15, 2023

Examiner les points de vue et les idées des experts sur les données les plus pertinentes sur le plan clinique pour le traitement de la leucémie lymphoïde chronique et du lymphome à cellules du manteau présentées lors des réunions annuelles de 2022 de l’ASCO, de l’EHA, de la Pan Pacific Lymphoma Conference, de l’ESMO et de la SOHO.

Othman Al-Sawaf, MD Matthew S. Davids, MD, MMSc Toby Eyre, MBChB, MD Christopher R. Flowers, MD, MS Brad S. Kahl, MD Kami Maddocks, MD Anthony Mato, MD, MSCE Lydia Scarfò, MD Julie M. Vose, MD, MBA Released: January 13, 2023

Erkenntnisse und Perspektiven von Experten zu klinisch relevanten Daten bei chronischer lymphatischer Leukämie und Mantelzell-Lymphom, die auf den Jahresversammlungen der ASCO, EHA, Pan Pacific Lymphoma Conference, ESMO und SOHO vorgestellt wurden.

Othman Al-Sawaf, MD Matthew S. Davids, MD, MMSc Toby Eyre, MBChB, MD Christopher R. Flowers, MD, MS Brad S. Kahl, MD Kami Maddocks, MD Anthony Mato, MD, MSCE Lydia Scarfò, MD Julie M. Vose, MD, MBA Released: January 13, 2023

Analisi delle prospettive e le intuizioni degli esperti sui dati più rilevanti dal punto di vista clinico per la leucemia linfatica cronica e il linfoma a cellule mantellari, presentati ai Congressi annuali 2022 di ASCO, EHA, Pan Pacific Lymphoma Conference, ESMO e SOHO.

Othman Al-Sawaf, MD Matthew S. Davids, MD, MMSc Toby Eyre, MBChB, MD Christopher R. Flowers, MD, MS Brad S. Kahl, MD Kami Maddocks, MD Anthony Mato, MD, MSCE Lydia Scarfò, MD Julie M. Vose, MD, MBA Released: January 13, 2023

Analise as perspectivas e os insights de especialistas sobre os dados clinicamente mais relevantes para leucemia linfocítica crônica e linfoma de células do manto apresentados nas Reuniões Anuais de 2022 da ASCO, EHA, Conferência Pan-Pacífico sobre Linfomas, ESMO e SOHO.

Othman Al-Sawaf, MD Matthew S. Davids, MD, MMSc Toby Eyre, MBChB, MD Christopher R. Flowers, MD, MS Brad S. Kahl, MD Kami Maddocks, MD Anthony Mato, MD, MSCE Lydia Scarfò, MD Julie M. Vose, MD, MBA Released: January 13, 2023

Lea las opiniones y comentarios expertos sobre los datos de mayor relevancia clínica de la leucemia linfocítica crónica y el linfoma de células del manto presentados en las Juntas Anuales de ASCO, EHA, la Conferencia Pan-Pacífico sobre Linfomas, ESMO y SOHO de 2022.

Othman Al-Sawaf, MD Matthew S. Davids, MD, MMSc Toby Eyre, MBChB, MD Christopher R. Flowers, MD, MS Brad S. Kahl, MD Kami Maddocks, MD Anthony Mato, MD, MSCE Lydia Scarfò, MD Julie M. Vose, MD, MBA Released: January 23, 2023
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings